Combination Treatment with GSK126 and Pomalidomide Induces B-Cell Differentiation in EZH2 Gain-of-Function Mutant Diffuse Large B-Cell Lymphoma

SIMPLE SUMMARY: To overcome the potential threat of drug resistance or limit of potency, the combination treatment of drugs is a promising strategy. Around 22% of patients with GCB-DLBCL carry EZH2 gain-of-function mutations and several PRC2 inhibitors are under clinical trials. Herein, we demonstra...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Sungryul, Jo, Seung-Hyun, Kim, Jong-Hwan, Kim, Seon-Young, Ha, Jae Du, Hwang, Jong Yeon, Lee, Myeong Youl, Kang, Jong Soon, Han, Tae-Su, Park, Sung Goo, Kim, Sunhong, Park, Byoung Chul, Kim, Jeong-Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565736/
https://www.ncbi.nlm.nih.gov/pubmed/32906688
http://dx.doi.org/10.3390/cancers12092541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565736/
https://www.ncbi.nlm.nih.gov/pubmed/32906688
http://dx.doi.org/10.3390/cancers12092541

Ejemplares similares